CAMBRIDGE, MA / ACCESSWIRE / May possibly 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology firm revolutionary messenger RNA (mRNA) therapeutics and vaccines, right now announced that that it will host its in-person Science and Technological innovation Working day for analysts and traders at 9:00 a.m. ET on Tuesday, Might 17 in Boston, MA.
Moderna’s Science and Technologies Day will aspect presentations from Stephen Hoge M.D., President, Melissa Moore Ph.D., Main Scientific Officer, Scientific Affairs, and Moderna’s mRNA and specialized enhancement system scientists with a focus on the Firm’s newest improvements from its determination to fundamental and utilized sciences.
A reside webcast will be obtainable under the “Occasions and Shows” in the Investors portion of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s web-site for 1 yr adhering to the presentation.
About Moderna
In more than 10 decades considering that its inception, Moderna has reworked from a exploration-phase enterprise advancing applications in the area of messenger RNA (mRNA) to an enterprise with a various clinical portfolio of vaccines and therapeutics throughout 7 modalities, a broad intellectual property portfolio in places together with mRNA and lipid nanoparticle formulation, and an integrated production plant that permits for quick clinical and professional output at scale. Moderna maintains alliances with a wide selection of domestic and overseas govt and business collaborators, which has authorized for the pursuit of both of those groundbreaking science and speedy scaling of manufacturing. Most recently, Moderna’s abilities have appear alongside one another to enable the licensed use and acceptance of a single of the earliest and most helpful vaccines against the COVID-19 pandemic.
Moderna’s mRNA system builds on continual innovations in simple and utilized mRNA science, delivery technologies and production, and has permitted the growth of therapeutics and vaccines for infectious diseases, immuno-oncology, scarce ailments, cardiovascular illnesses and automobile-immune disorders. Moderna has been named a leading biopharmaceutical employer by Science for the past seven many years. To learn a lot more, pay a visit to www.modernatx.com.
Moderna Contact:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
Resource: Moderna, Inc.
Look at source edition on accesswire.com:
https://www.accesswire.com/699496/Moderna-to-Host-Annual-Science-and-Technology-Working day-on-May possibly-17-2022
